ArticleInternational journal of dermatology2026
Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.
Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.International journal of dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuselkumab, a selective interleukin (IL)-23 inhibitor, is approved for the treatment of moderate-to-severe plaque psoriasis. While randomized clinical trials have introduced the concept of "super-responders" (SRe)-patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100) at defined early timepoints-real-world evidence on their characteristics and long-term outcomes remains limited. This study aimed to identify baseline predictors of super-response (PASI 100 at Weeks 16 and 24) and to evaluate long-term effectiveness, safety, and drug survival over a 5-year period in a routine clinical setting.
methodsThis retrospective multicenter study analyzed 435 patients from the Czech BIOREP registry treated with guselkumab. Predictors of super-response were identified using multivariable logistic regression. PASI outcomes and drug survival were assessed with descriptive statistics and Kaplan-Meier analysis.
resultsAmong the cohort, 130 patients (29.9%) were classified as super-responders. Lower body mass index (BMI) and absence of prior biologic therapy were independent predictors of SRe status (odds ratio [OR] = 0.94 and 0.73, respectively). While PASI 75/90/100 rates were significantly higher in SRe throughout follow-up, drug survival was comparable between SRe and non-SRe. At 60 months, PASI 100 was maintained in 79.2% of SRe versus 35.4% of non-SRe. Obesity and female sex were associated with lower long-term treatment persistence.
conclusionsSuper-response to guselkumab is linked to distinct baseline features. Despite differences in PASI outcomes, treatment persistence was similar across groups. These findings underscore the value of early identification of super-responders and support personalized treatment strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.